Evaluation of the safety profile of the quadrivalent vaccine against human papillomavirus in the risk of developing autoimmune, neurological, and hematological diseases in adolescent women in Colombia

被引:1
|
作者
Maldonado, Ivette [1 ,2 ]
Nino, Nicolas Rodriguez [1 ]
Valencia, Carlos F. [3 ]
Ortiz, Daniela [3 ]
Ayala, Nathalia [2 ]
D'silva, Liz [2 ]
Villarreal, Santiago Castro [3 ]
Salazar, Diego [3 ]
Lozano, Catalina [3 ]
Angulo, Daniela [3 ,4 ]
机构
[1] Fdn Santa Fe Bogota, Dept Gynecol Obstet & Human Reprod, Bogota, Colombia
[2] Univ Ios Andes, Sch Med, Bogota, Colombia
[3] Univ Ios Andes, Dept Ind Engn, Bogota, Colombia
[4] Univ Michigan, Dept Biostat, Ann Arbor, MI USA
关键词
Human Papillomavirus; Vaccine; Safety; Adolescent Health; Women Health; HPV VACCINATION; SURVEILLANCE; DISORDERS;
D O I
10.1016/j.vaccine.2024.02.085
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Cervical cancer eradication is one of the main goals for 2030 by the World Health Organization, which can only be achieved with high vaccination rates against Human Papilloma Virus. In Colombia, more and better scientific evidence is required to increase confidence in vaccination. The objective of this study is to evaluate the safety profile of the quadrivalent vaccine against HPV in the risk of developing autoimmune, neurological, and hematological diseases in adolescent women in Colombia. Methods: We designed a cohort study based on national HPV vaccination records and incident diagnostic data for the diseases of special interest during 2012 and 2021. We included adolescent women between 9 and 19 years old and compared vaccinated and non -vaccinated cohorts using an Inverse Probability of Treatment Weighting (IPWT) method for each scenario disease and follow-up period (180 and 360 days). Findings: The Odds Ratio (OR) of developing diseases of interest was estimated during two follow up periods, 180 and 360 days after the follow-up index date (Vaccination Day). The OR for developing rheumatoid arthritis was 4.4; CI95% (1.74 - 11.14), juvenile idiopathic arthritis was 2.76 IC95% (1.50 - 5.11), idiopathic thrombocytopenic purpura was 2.54 IC95% (1.28 - 5.02) and thyrotoxicosis was 2.86 IC95% (1.03 - 7.95), when comparing the vaccinated versus unvaccinated population. However, the temporal distribution of cases incident did not reveal a clear difference between the cohorts, since the rate of appearance of new cases has a constant linear behavior for the two groups. Interpretation: For rheumatoid arthritis, juvenile idiopathic arthritis, idiopathic thrombocytopenic purpura, and thyrotoxicosis; the application of the vaccine had an effect on the development of the disease. Nevertheless, our results should be interpreted with caution and be further studied, considering that the biological plausibility of the events occurred without a clear temporal pattern in relation to the exposure to the vaccine.
引用
收藏
页码:2414 / 2420
页数:7
相关论文
共 33 条
  • [21] Human papillomavirus vaccine-related risk perceptions and subsequent sexual behaviors and sexually transmitted infections among vaccinated adolescent women
    Mullins, Tanya L. Kowalczyk
    Zimet, Gregory D.
    Rosenthal, Susan L.
    Morrow, Charlene
    Ding, Lili
    Huang, Bin
    Kahn, Jessica A.
    VACCINE, 2016, 34 (34) : 4040 - 4045
  • [22] Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women
    Perez, Gonzalo
    Lazcano-Ponce, Eduardo
    Hernandez-Avila, Mauricio
    Garcia, Patricia J.
    Munoz, Nubia
    Villa, Luisa L.
    Bryan, Janine
    Taddeo, Frank J.
    Lu, Shuang
    Esser, Mark T.
    Vuoco, Scott
    Sattler, Carlos
    Barr, Eliav
    INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (06) : 1311 - 1318
  • [23] Impact of quadrivalent human papillomavirus vaccine in women at increased risk of genital warts burden: Population-based cross-sectional survey of Czech women aged 16 to 40 years
    Petras, Marek
    Adamkova, Vera
    VACCINE, 2015, 33 (46) : 6264 - 6267
  • [24] Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up
    Wei, Lihui
    Xie, Xing
    Liu, Jihong
    Zhao, Yun
    Chen, Wen
    Zhao, Chao
    Wang, Shaoming
    Liao, Xueyan
    Shou, Qiong
    Qiu, Yuanzheng
    Qiao, Youlin
    Saah, Alfred J.
    VACCINE, 2019, 37 (27) : 3617 - 3624
  • [25] Risk of Autoimmune Diseases (AD) After Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine Immunization in Women Aged 9 to 25 Years in the United Kingdom: An Observational Cohort Study
    Willame, Corinne
    Rosillon, Dominique
    Zima, Julia
    Angelo, Maria-Genalin
    Stuurman, Anke
    Vroling, Hilde
    van Staa, Tjeerd
    Boggon, Rachael
    Bunge, Eveline
    Pladevall-Vila, Manel
    Baril, Laurence
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 409 - 409
  • [26] Safety and Immunogenicity Profile of Human Papillomavirus-16/18 AS04 Adjuvant Cervical Cancer Vaccine: A Randomized Controlled Trial in Healthy Adolescent Girls of Bangladesh
    Khatun, Sabera
    Hussain, Syed Md Akram
    Chowdhury, Sameena
    Ferdous, Jannatul
    Hossain, Fawzia
    Begum, Sultana Razia
    Jahan, Munira
    Tabassum, Shahina
    Khatun, Shahla
    Karim, A. B. M. Fazlul
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (01) : 36 - 41
  • [27] Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial
    Munoz, Nubia
    Manalastas, Ricardo, Jr.
    Pitisuttithum, Punee
    Tresukosol, Damrong
    Monsonego, Joseph
    Ault, Kevin
    Clavel, Christine
    Luna, Joaquin
    Myers, Evan
    Hood, Sara
    Bautista, Oliver
    Bryan, Janine
    Taddeo, Frank J.
    Esser, Mark T.
    Vuocolo, Scott
    Haupt, Richard M.
    Barr, Eliav
    Saah, Alfred
    LANCET, 2009, 373 (9679): : 1949 - 1957
  • [28] Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up
    Chen, Wen
    Zhao, Yun
    Xie, Xing
    Liu, Jihong
    Li, Jingran
    Zhao, Chao
    Wang, Shaoming
    Liao, Xueyan
    Shou, Qiong
    Zheng, Minghuan
    Saah, Alfred J.
    Wei, Lihui
    Qiao, Youlin
    VACCINE, 2019, 37 (06) : 889 - 897
  • [29] Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing
    Lehtinen, Matti
    Apter, Dan
    Dubin, Gary
    Kosunen, Elise
    Isaksson, Rita
    Korpivaara, Eeva-Leena
    Kyha-Osterlund, Laura
    Lunnas, Terhi
    Luostarinen, Tapio
    Niemi, Lubov
    Palmroth, Johanna
    Petaja, Tiina
    Rekonen, Sirpa
    Salmivesi, Susanna
    Siitari-Mattila, Mari
    Svartsjo, Sofia
    Tuomivaara, Leena
    Vilkki, Marjo
    Pukkala, Eero
    Paavonen, Jorma
    INTERNATIONAL JOURNAL OF STD & AIDS, 2006, 17 (08) : 517 - 521
  • [30] Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia
    Brotherton, Julia M. L.
    Malloy, Michael
    Budd, Alison C.
    Saville, Marion
    Drennan, Kelly T.
    Gertig, Dorota M.
    PAPILLOMAVIRUS RESEARCH, 2015, 1 : 59 - 73